Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
EGRX Eagle Pharmaceuticals, Inc. daily Stock Chart
EGRX [NASD]
Eagle Pharmaceuticals, Inc.
Healthcare | Drugs - Generic | USA
statements
Index- P/E29.37 EPS (ttm)1.78 Insider Own12.40% Shs Outstand13.93M Perf Week-6.27%
Market Cap728.54M Forward P/E17.12 EPS next Y3.06 Insider Trans-4.37% Shs Float11.94M Perf Month-10.40%
Income25.90M PEG26.70 EPS next Q0.49 Inst Own97.70% Short Float15.63% Perf Quarter-7.97%
Sales203.70M P/S3.58 EPS this Y-40.00% Inst Trans-0.21% Short Ratio13.61 Perf Half Y-10.06%
Book/sh12.86 P/B4.07 EPS next Y18.41% ROA10.20% Target Price57.00 Perf Year20.59%
Cash/sh8.41 P/C6.22 EPS next 5Y1.10% ROE15.10% 52W Range44.04 - 64.94 Perf YTD-12.95%
Dividend- P/FCF7.54 EPS past 5Y37.60% ROI16.80% 52W High-20.16% Beta1.07
Dividend %- Quick Ratio4.10 Sales past 5Y73.20% Gross Margin66.70% 52W Low17.73% ATR1.67
Employees96 Current Ratio4.20 Sales Q/Q-19.90% Oper. Margin17.00% RSI (14)30.77 Volatility2.67% 2.87%
OptionableYes Debt/Eq0.23 EPS Q/Q-119.30% Profit Margin12.70% Rel Volume0.47 Prev Close52.30
ShortableYes LT Debt/Eq0.20 EarningsFeb 27 BMO Payout0.00% Avg Volume137.18K Price51.85
Recom2.20 SMA20-6.60% SMA50-10.27% SMA200-8.94% Volume43,241 Change-0.86%
Nov-01-18Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-18Downgrade Piper Jaffray Overweight → Neutral
Mar-21-18Reiterated Mizuho Underperform $37 → $40
Nov-09-17Reiterated RBC Capital Mkts Outperform $81 → $75
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Jul-29-15Reiterated Piper Jaffray Overweight $94 → $119
Feb-19-20 04:30PM  Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 Business Wire
Feb-13-20 07:50AM  Eagle Pharmaceuticals (NASDAQ:EGRX) Has A Pretty Healthy Balance Sheet Simply Wall St.
Feb-10-20 09:54AM  Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY (Pemetrexed for Injection) Business Wire
Jan-13-20 06:50AM  Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimers Disease in Collaboration With University of Pennsylvania Business Wire
Jan-09-20 08:40AM  Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study Zacks
06:50AM  Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke Business Wire
Jan-08-20 10:18AM  Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up Zacks
08:16AM  Is Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) ROE Of 15% Concerning? Simply Wall St.
Jan-07-20 09:25AM  Tyme stock rises on Eage collaboration for cancer drug MarketWatch
07:20AM  Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer Business Wire
Jan-06-20 06:50AM  Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury Business Wire
Dec-23-19 06:50AM  Eagle Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-16-19 06:50AM  Eagle Pharmaceuticals Granted Orphan Drug Designation for RYANODEX (dantrolene sodium) for Treatment of Organophosphate Exposure (Nerve Agents) Business Wire
Dec-13-19 02:53PM  Eagle Pharmaceuticals Reaches Settlement Agreement with Eli Lilly for PEMFEXY (pemetrexed for injection) Business Wire
Dec-11-19 11:25AM  Eagle Pharmaceuticals Inc (EGRX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-09-19 06:50AM  Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate Business Wire
Dec-03-19 08:45AM  If You Had Bought Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Five Years Ago, You Could Pocket A 336% Gain Today Simply Wall St.
Nov-21-19 07:49AM  Edited Transcript of EGRX earnings conference call or presentation 12-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-20-19 06:50AM  Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-19 06:50AM  Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors Business Wire
Nov-12-19 08:15AM  Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates Zacks -5.61%
06:51AM  Eagle Pharmaceuticals Reports Third Quarter 2019 Results Business Wire
06:50AM  Eagle Pharmaceuticals Announces Enrollment of Additional Exertional Heat Stroke Patients at the 2019 Hajj Pilgrimage Business Wire
Nov-09-19 02:26PM  Do Hedge Funds Love Eagle Pharmaceuticals Inc (EGRX)? Insider Monkey
Nov-05-19 10:31AM  Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-31-19 04:30PM  Eagle Pharmaceuticals to Discuss Third Quarter 2019 Financial Results on November 12, 2019 Business Wire
10:34AM  Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-19 08:02AM  An Intrinsic Calculation For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Suggests It's 39% Undervalued Simply Wall St.
Oct-17-19 09:28AM  New Strong Sell Stocks for October 17th Zacks
Oct-07-19 06:50AM  Eagle Pharmaceuticals Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation Business Wire
Oct-02-19 02:39PM  Here's What Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) P/E Is Telling Us Simply Wall St.
Sep-24-19 11:30AM  Zacks.com featured highlights include: Garmin, Eagle Pharmaceuticals, BMC Stock, SeaWorld and Zumiez Zacks
Sep-23-19 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 2019 Cantor Global Healthcare Conference Business Wire
08:32AM  5 Momentum Picks Screened on Driehaus Strategy Zacks
Sep-10-19 07:29AM  Does The Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Share Price Tend To Follow The Market? Simply Wall St.
Sep-04-19 08:40AM  Insulet (PODD) Catches Eye: Stock Jumps 8.9% Zacks
Aug-30-19 01:49PM  Edited Transcript of EGRX earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-28-19 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference Business Wire
Aug-20-19 04:47PM  Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta Zacks
Aug-18-19 10:21AM  Should Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Be Your Next Stock Pick? Simply Wall St.
Aug-14-19 10:29AM  New Strong Buy Stocks for August 14th Zacks
Aug-09-19 06:23AM  Eagle Pharmaceuticals Inc (EGRX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 08:45AM  Eagle Pharmaceuticals (EGRX) Beats Q2 Earnings and Revenue Estimates Zacks
06:50AM  Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results Business Wire
Aug-05-19 06:50AM  Eagle Pharmaceuticals Announces Clinical Development Plan of Innovative Product Intended to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor (ER)-Positive Breast Cancer Business Wire
Aug-01-19 10:33AM  Earnings Preview: Eagle Pharmaceuticals (EGRX) Q2 Earnings Expected to Decline Zacks
Jul-29-19 04:30PM  Eagle Pharmaceuticals to Discuss Second Quarter 2019 Financial Results on August 8, 2019 Business Wire
Jul-26-19 07:54AM  Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt? Simply Wall St.
Jul-03-19 01:59PM  Should You Worry About Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Pay Cheque? Simply Wall St.
08:48AM  Park Service diverts $2.5 million in fees to pay for Trumps July 4th celebration | Beto ORourke says hes unaware of his fundraising numbers MarketWatch
May-31-19 03:07PM  Here's Why I Think Eagle Pharmaceuticals (NASDAQ:EGRX) Might Deserve Your Attention Today Simply Wall St.
May-28-19 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference Business Wire
May-15-19 06:34PM  Edited Transcript of EGRX earnings conference call or presentation 7-May-19 12:30pm GMT Thomson Reuters StreetEvents
04:30PM  Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference Business Wire
May-09-19 08:43PM  Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc (EGRX) Insider Monkey
May-08-19 06:00AM  Can Eagle Pharma Fly through its Oncology Trials MoneyShow
May-07-19 12:23PM  Eagle Pharmaceuticals Inc (EGRX) Q1 2019 Earnings Call Transcript Motley Fool +6.89%
08:05AM  Eagle Pharmaceuticals (EGRX) Beats Q1 Earnings and Revenue Estimates Zacks
07:04AM  Did You Miss Eagle Pharmaceuticals's (NASDAQ:EGRX) Whopping 457% Share Price Gain? Simply Wall St.
06:58AM  Eagle Pharmaceuticals: 1Q Earnings Snapshot Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results Business Wire
06:45AM  Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure Business Wire
Apr-30-19 10:32AM  Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-29-19 06:50AM  Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019 Business Wire
Apr-22-19 09:48AM  New Strong Sell Stocks for April 22nd Zacks
06:50AM  CMS Establishes Unique J-Code for BELRAPZO (Bendamustine 500mL Hydrochloride Injection) Business Wire
Apr-15-19 06:50AM  Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA with Teva Pharmaceuticals International GmbH Business Wire
Apr-03-19 02:09PM  Don't Sell Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Before You Read This Simply Wall St.
Mar-28-19 07:35AM  Consolidated Research: 2019 Summary Expectations for Penn National Gaming, Nomad Foods, Americold Realty Trust, Cboe Global Markets, Eagle Pharmaceuticals, and National Commerce Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-07-19 12:02AM  Edited Transcript of EGRX earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 02:44PM  Eagle Pharmaceuticals Inc (EGRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:50AM  Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results Business Wire
06:30AM  Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-21-19 11:06AM  Is Eagle Pharmaceuticals, Inc.s (NASDAQ:EGRX) ROE Of 15% Impressive? Simply Wall St.
10:31AM  Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-19-19 04:30PM  Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019 Business Wire
Feb-18-19 10:30AM  Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline Zacks
Feb-14-19 09:10AM  Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock? Zacks
Jan-04-19 06:51AM  Does Eagle Pharmaceuticals, Inc.s (NASDAQ:EGRX) CEO Pay Matter? Simply Wall St. +5.67%
Jan-02-19 07:00AM  Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-16-18 10:49PM  Hedge Funds Are Selling Eagle Pharmaceuticals Inc (EGRX) Insider Monkey
Nov-30-18 07:45AM  Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-27-18 06:50AM  Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS) Business Wire
Nov-26-18 09:05AM  Investors Are Undervaluing Eagle Pharmaceuticals Inc (NASDAQ:EGRX) By 28.8% Simply Wall St.
Nov-19-18 07:00AM  Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-16-18 04:32AM  Moving Average Crossover Alert: Eagle Pharmaceuticals (EGRX) Zacks
Nov-07-18 11:10AM  Edited Transcript of EGRX earnings conference call or presentation 1-Nov-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-01-18 10:41AM  Eagle Pharmaceuticals (EGRX) Q3 Earnings Match Estimates Zacks +6.07%
08:21AM  Eagle Pharmaceuticals: 3Q Earnings Snapshot Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results Business Wire
Oct-30-18 06:50AM  Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase as Part of New $150 Million Share Repurchase Authorization Business Wire -16.52%
06:45AM  Eagle Pharmaceuticals Announces Results of Study for Fulvestrant Business Wire
Oct-25-18 05:00PM  Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2018 Financial Results on November 1, 2018 Business Wire
Oct-23-18 07:25AM  Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-19-18 09:28AM  Is Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Attractive At Its Current PE Ratio? Simply Wall St.
Oct-03-18 07:00AM  Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure Business Wire
Sep-27-18 07:00AM  Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference Business Wire
Sep-26-18 04:30PM  Eagle Appoints David Pernock to Position of Chief Operating Officer Business Wire
Sep-11-18 10:41AM  Does Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Fall With The Market? Simply Wall St.
Sep-07-18 08:32AM  Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod Zacks
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hudson Executive Capital LPDirectorOct 25Sale63.5715,437981,302732,777Oct 28 04:40 PM
Hudson Executive Capital LPDirectorOct 24Sale62.531,49493,412748,214Oct 28 04:40 PM
Hudson Executive Capital LPDirectorOct 23Sale62.5820012,516749,708Oct 23 06:58 PM
Hudson Executive Capital LPDirectorOct 22Sale62.686,567411,618749,908Oct 23 06:58 PM
Hudson Executive Capital LPDirectorOct 21Sale62.563,849240,791756,475Oct 23 06:58 PM
Hudson Executive Capital LPDirectorOct 18Sale62.611,600100,174760,324Oct 18 05:29 PM
Hudson Executive Capital LPDirectorOct 17Sale62.5813,842866,196761,924Oct 18 05:29 PM
Hudson Executive Capital LPDirectorOct 16Sale62.501026,375775,766Oct 18 05:29 PM
Hudson Executive Capital LPDirectorOct 15Sale62.633,909244,836775,868Oct 15 06:24 PM
Hudson Executive Capital LPDirectorOct 11Sale60.3916,300984,419779,777Oct 15 06:24 PM
Hudson Executive Capital LPDirectorOct 10Sale60.167,829471,002796,077Oct 15 06:24 PM
Hudson Executive Capital LPDirectorOct 08Sale60.031,55893,520803,906Oct 09 04:13 PM
Hudson Executive Capital LPDirectorOct 07Sale60.114,901294,600805,464Oct 09 04:13 PM
Hudson Executive Capital LPDirectorSep 17Sale60.001006,000810,365Sep 19 04:13 PM
Hudson Executive Capital LPDirectorSep 12Sale60.0720012,014810,465Sep 13 04:43 PM
Hudson Executive Capital LPDirectorSep 11Sale60.061,11266,785810,665Sep 13 04:43 PM
Braunstein Douglas LDirectorMay 10Sale56.14100,0005,614,000811,777May 13 05:52 PM
Braunstein Douglas LDirectorMay 09Sale57.9559,2233,431,973911,777May 13 05:52 PM
Tarriff ScottCEOApr 01Sale50.1524,9751,252,4961,500,202Apr 03 04:33 PM
FLAUM SANDER ADirectorMar 05Option Exercise4.042,3409,45413,714Mar 06 04:41 PM
RATOFF STEVEN BDirectorMar 04Option Exercise4.042,3409,45418,004Mar 06 04:42 PM
Tarriff ScottCEOMar 01Sale51.1724,4281,250,0151,525,177Mar 04 04:31 PM
open in yahoo | open in reuters | open in google